SCHEMBL27769160

SCHEMBL27769160

Nc1ccc2ccc(=O)n(N)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRPF1 P55201 3/20 0.52
▸ ALDH1A1 P00352 5/20 0.38
▸ MAPT P10636 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ GFER P55789 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ CYP3A4 P08684 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ HBB P68871 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ F2 P00734 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11743970 0.78 BRPF1 (0.76) BRPF1ALDH1A1MAPTKDM4EGFER
SCHEMBL1055201 0.74 CA12 (0.57) BRPF1ALDH1A1MAPTKDM4EMEN1
SCHEMBL26597051 0.73 BRPF1 (0.50) BRPF1ALDH1A1MAPTKDM4EGFER
SCHEMBL4949297 0.70 PRKCI (0.45) BRPF1ALDH1A1MAPTKDM4EGFER
SCHEMBL7085783 0.68 BRPF1 (1.00) BRPF1ALDH1A1MAPTKDM4EGFER
SCHEMBL17576257 0.64 BRPF1 (0.62) BRPF1ALDH1A1MAPTKDM4EGFER
SCHEMBL29981364 0.64 PDE3B (0.39) CYP3A4LMNAKDR
SCHEMBL398452 0.64 PRKCI (0.70) BRPF1ALDH1A1MAPTKDM4ECYP3A4
SCHEMBL4951509 0.64 PRKCI (0.44) BRPF1ALDH1A1MAPTKDM4ECYP3A4
SCHEMBL29507010 0.64 PRKCI (0.70) BRPF1ALDH1A1MAPTKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118766947-A Methods for treating SARS CoV-2 infection 吉利德科学公司 2024-10-15 — — CN claimed
CN-118662520-A Methods for treating SARS CoV-2 infection 吉利德科学公司 2024-09-20 — — CN claimed
CN-114641299-A Methods for treating SARS CoV-2 infection 吉利德科学公司 2022-06-17 — — CN claimed
CN-114245807-B FLT3L-FC fusion proteins and methods of use 吉利德科学公司 2025-05-02 — — CN disclosed
CN-119604286-A Methods for treating viral infections including SARS-COV-2 吉利德科学公司 2025-03-11 — — CN disclosed
CN-115175735-B Antiviral compounds 吉利德科学公司 2025-03-04 — — CN disclosed
CN-118900839-A Antiviral compounds and methods of making and using the same 吉利德科学公司 2024-11-05 — — CN disclosed
CN-118852172-A 5- (4-Aminopyrrolo [2,1-f ] [1,2,4] triazin-7-yl) -2-cyano-3, 4-dihydroxytetrahydrofuran derivatives as antiviral agents 吉利德科学公司 2024-10-29 — — CN disclosed
CN-118843629-A Antiviral compounds and methods of making and using the same 吉利德科学公司 2024-10-25 — — CN disclosed
CN-118786128-A Compounds and methods for treating viral infections 吉利德科学公司 2024-10-15 — — CN disclosed
CN-118766947-A Methods for treating SARS CoV-2 infection 吉利德科学公司 2024-10-15 — — CN disclosed
CN-117982682-A Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections 吉利德科学公司 2024-05-07 — — CN disclosed
CN-117858881-A Phospholipid compounds and methods of making and using the same 吉利德科学公司 2024-04-09 — — CN disclosed
CN-116568688-A Compounds and methods for treating viral infections 吉利德科学公司 2023-08-08 — — CN disclosed
CN-116322759-A Phospholipid compounds and uses thereof 吉利德科学公司 2023-06-23 — — CN disclosed
CN-115996928-A 1' -cyanonucleoside analogs and uses thereof 吉利德科学公司 2023-04-21 — — CN disclosed
CN-115362004-A Inhalation formulations of 1' -cyano-substituted carbon nucleoside analogs 吉利德科学公司 2022-11-18 — — CN disclosed
CN-115135383-A Antiviral compounds 吉利德科学公司 2022-09-30 — — CN disclosed
CN-114245807-A FLT3L-FC fusion proteins and methods of use 吉利德科学公司 2022-03-25 — — CN disclosed
CN-101589038-A Heterocyclidene-N-(aryl)acetamide derivative MOCHIDA PHARM CO LTD (JP) 2009-11-25 — — CN disclosed
Send feedback